Response to DNA damage of CHEK2 missense mutations in familial breast cancer

Human Molecular Genetics

Volumn 21, Issue 12, 2012, Pages 2738-2744

  Roeb, Wendy ^a   Higgins, Jake ^a,b   King, Mary Claire ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2;

ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; COMPUTER MODEL; DNA DAMAGE; FAMILIAL CANCER; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; WILD TYPE;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; DNA DAMAGE; FAMILY HEALTH; FEMALE; GENETIC COMPLEMENTATION TEST; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEDIGREE; PROTEIN-SERINE-THREONINE KINASES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84861747135     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds101     Document Type: Article

References (32)

1. Walsh, T., Lee, M.K., Casadei, S., Thornton, A.M., Stray, S.M., Pennil, C., Nord, A.S., Mandell, J.B., Swisher, E.M. and King, M.C. (2010) Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl Acad. Sci. USA, 107, 12629-12633.
2. Matsuoka, S., Huang, M. and Elledge, S.J. (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science, 282, 1893-1897.
3. Hirao, A., Kong, Y.Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S.J. and Mak, T.W. (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science, 287, 1824-1827.
4. Sodha, N., Mantoni, T.S., Tavtigian, S.V., Eeles, R. and Garrett, M.D. (2006) Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. Cancer Res., 66, 8966-8970.
5. Oliver, A.W., Paul, A., Boxall, K.J., Barrie, S.E., Aherne, G.W., Garrett, M.D., Mittnacht, S. and Pearl, L.H. (2006) Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J., 25, 3179-3190.
6. Cai, Z., Chehab, N.H. and Pavletich, N.P. (2009) Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol. Cell, 35, 818-829.
7. Schwarz, J.K., Lovly, C.M. and Piwnica-Worms, H. (2003) Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res., 1, 598-609.
8. Chrisanthar, R., Knappskog, S., Lokkevik, E., Anker, G., Ostenstad, B., Lundgren, S., Berge, E.O., Risberg, T., Mjaaland, I., Maehle, L. et al. (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS ONE, 3, e3062.
9. Wu, X., Webster, S.R. and Chen, J. (2001) Characterization of tumor-associated Chk2 mutations. J. Biol. Chem., 276, 2971-2974.
10. Lee, S.B., Kim, S.H., Bell, D.W., Wahrer, D.C., Schiripo, T.A., Jorczak, M.M., Sgroi, D.C., Garber, J.E., Li, F.P., Nichols, K.E. et al. (2001) Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res., 61, 8062-8067.
11. Bell, D.W., Varley, J.M., Szydlo, T.E., Kang, D.H., Wahrer, D.C., Shannon, K.E., Lubratovich, M., Verselis, S.J., Isselbacher, K.J., Fraumeni, J.F. et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science, 286, 2528-2531.
12. Hollestelle, A., Wasielewski, M., Martens, J.W. and Schutte, M. (2010) Discovering moderate-risk breast cancer susceptibility genes. Curr. Opin. Genet. Dev., 20, 268-276.
13. Ingvarsson, S., Sigbjornsdottir, B.I., Huiping, C., Hafsteinsdottir, S.H., Ragnarsson, G., Barkardottir, R.B., Arason, A., Egilsson, V. and Bergthorsson, J.T. (2002) Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res., 4, R4.
14. Dong, X., Wang, L., Taniguchi, K., Wang, X., Cunningham, J.M., McDonnell, S.K., Qian, C., Marks, A.F., Slager, S.L., Peterson, B.J. et al. (2003) Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet., 72, 270-280.
15. CHEK2 Breast Cancer Case-Control Consortium. (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am. J. Hum. Genet., 74, 1175-1182.
16. Narod, S.A. (2010) Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin. Genet., 78, 1-7.
17. Le Calvez-Kelm, F., Lesueur, F., Damiola, F., Vallee, M., Voegele, C., Babikyan, D., Durand, G., Forey, N., McKay-Chopin, S., Robinot, N. et al. (2011) Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res., 13, R6.
18. Casadei, S., Norquist, B.M., Walsh, T., Stray, S., Mandell, J.B., Lee, M.K., Stamatoyannopoulos, J.A. and King, M.C. (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res., 71, 2222-2229.
19. Wu, X., Dong, X., Liu, W. and Chen, J. (2006) Characterization of CHEK2 mutations in prostate cancer. Hum. Mutat., 27, 742-747.
20. Nevanlinna, H. and Bartek, J. (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene, 25, 5912-5919.
21. Zhao, X., Georgieva, B., Chabes, A., Domkin, V., Ippel, J.H., Schleucher, J., Wijmenga, S., Thelander, L. and Rothstein, R. (2000) Mutational and structural analyses of the ribonucleotide reductase inhibitor Sml1 define its Rnr1 interaction domain whose inactivation allows suppression of mec1 and rad53 lethality. Mol. Cell Biol., 20, 9076-9083.
22. Lundin, C., North, M., Erixon, K., Walters, K., Jenssen, D., Goldman, A.S. and Helleday, T. (2005) Methyl methanesulfonate (MMS) produces heat-labile DNA damage but no detectable in vivo DNA double-strand breaks. Nucleic Acids Res., 33, 3799-3811.
23. Shaag, A., Walsh, T., Renbaum, P., Kirchhoff, T., Nafa, K., Shiovitz, S., Mandell, J.B., Welcsh, P., Lee, M.K., Ellis, N. et al. (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum. Mol. Genet., 14, 555-563.
24. Falck, J., Mailand, N., Syljuasen, R.G., Bartek, J. and Lukas, J. (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature, 410, 842-847.
25. Tavtigian, S.V., Greenblatt, M.S., Lesueur, F. and Byrnes, G.B. (2008) In silico analysis of missense substitutions using sequence-alignment based methods. Hum. Mutat., 29, 1327-1336.
26. Mathe, E., Olivier, M., Kato, S., Ishioka, C., Hainaut, P. and Tavtigian, S.V. (2006) Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res., 34, 1317-1325.
27. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S. and Sunyaev, S.R. (2010) A method and server for predicting damaging missense mutations. Nat. Methods, 7, 248-249.
28. Ng, P.C. and Henikoff, S. (2001) Predicting deleterious amino acid substitutions. Genome Res., 11, 863-874.
29. Chan, P.A., Duraisamy, S., Miller, P.J., Newell, J.A., McBride, C., Bond, J.P., Raevaara, T., Ollila, S., Nystrom, M., Grimm, A.J. et al. (2007) Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum. Mutat., 28, 683-693.
30. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M.O., Lehman, C.D., Morris, E., Pisano, E., Schnall, M., Sener, S. et al. (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin., 57, 75-89.
31. Antoni, L., Sodha, N., Collins, I. and Garrett, M.D. (2007) CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat. Rev. Cancer, 7, 925-936.
32. Tavtigian, S.V., Byrnes, G.B., Goldgar, D.E. and Thomas, A. (2008) Classification of raremissense substitutions, using risk surfaces, with geneticand molecular-epidemiology applications. Hum. Mutat., 29, 1342-1354.